Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Webcast ImageWebcast
Q1 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call  (Live)
04/30/15 at 9:00 a.m. ET
Q1 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Thursday, April 30, 2015 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$84.65
Change (%) Stock is Up 1.18 (1.41%)
Volume1,151,626
Data as of 04/17/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
04/16/15Pacira Receives Subpoena from the U.S. Department of Justice
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the ... 
Printer Friendly Version
04/13/15Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 13, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2015 will be released before the market opens on Thursday, April 30, 2015. The Pacira management team will also host a conference call to discuss the company’s financial results and recent and upcoming developments at 9 a.m. ET on Thursday, April 30, 2015. The call can ... 
Printer Friendly Version
04/10/15Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 10, 2015-- Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to manage postsurgical pain following total knee replacement surgery. The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to ... 
Printer Friendly Version
03/26/15Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
-- Results Presented at the 2015 Annual Meeting of the American Academy of Orthopedic Surgeons Find Overall Hospital Cost Savings of More Than $1.5 Million -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 26, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating the benefits associated with the use of EXPAREL® (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patient... 
Printer Friendly Version

Corporate Presentation

DateTitle
03/16/15
Corporate Presentation
01/22/15
Analyst Day Presentation
Upcoming EventsMore >>
DateTitle
04/30/15 9:00 a.m. ET
Q1 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com